XML 38 R26.htm IDEA: XBRL DOCUMENT
v3.21.2

Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies (Details Textual) |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 24, 2020 | Jun. 30, 2017 USD ($) | Jun. 30, 2017 EUR (€) | Aug. 31, 2021 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2020 USD ($) | Jul. 26, 2021 | Jul. 08, 2021 shares | Dec. 31, 2020 USD ($) | Dec. 01, 2020 | Apr. 26, 2019 | Jun. 30, 2017 EUR (€)
Cost of Goods and Services Sold, Total |  |  |  |  | $ 392,544 | $ 266,929 | $ 1,612,810 | $ 1,169,351 |  |  |  |  |  |
Collaborative Arrangement, Payment for Research and Development Agreement |  | $ 1,100,000 |  |  |  |  |  |  |  |  |  |  |  |
ID Biologics Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of Goods and Services Sold, Total |  |  |  |  | $ 76,000 |  | $ 132,000 |  |  |  |  |  |  |
Novovet [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Method Investment, Ownership Percentage |  |  |  |  |  |  |  |  |  |  |  |  | 20.00% |
Alphazyme [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sale of Stock, Percentage of Ownership after Transaction | 2.50% |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Securities without Readily Determinable Fair Value, Amount |  |  |  |  |  |  |  |  |  |  | $ 284,709 |  |  |
BDI Holdings [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from Sales of Business, Affiliate and Productive Assets |  |  |  | $ 1,600,000 |  |  |  |  |  |  |  |  |  |
Research Services Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Payment for Additional Development and Commercialization | € |  |  |  |  |  |  |  |  |  |  |  |  |  | € 1,500,000
Service Framework Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Minimum Obligation For Research and Development |  | $ 1,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Duration Of Agreement (Year) |  | 2 years | 2 years |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Outstanding Commitment |  | $ 1,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |
BDI Holdings [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership Percentage |  |  |  |  |  |  |  |  | 16.10% |  |  |  |  |
VLPBio Member |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership Percentage |  |  |  |  |  |  |  |  | 3.30% |  |  |  |  |
Alphazyme [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership Percentage |  |  |  |  |  |  |  |  |  |  |  | 1.99% |  |
ID Biologics Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investment Owned, Balance, Shares (in shares) | shares |  |  |  |  |  |  |  |  |  | 129,661 |  |  |  |
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners |  |  |  |  |  |  |  |  |  | 0.37% |  |  |  |
Research Services Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Payment for Research and Development Agreement | € |  |  | € 1,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Research Services Agreement [Member] | BDI Holdings [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Equity Interest Acquired |  | 16.10% | 16.10% |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Minimum Obligation For Research and Development | € |  |  |  |  |  |  |  |  |  |  |  |  |  | 936,000
Collaborative Arrangement, Duration Of Agreement (Year) |  | 2 years | 2 years |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Maximum Obligation For Research and Development | € |  |  |  |  |  |  |  |  |  |  |  |  |  | 8,000,000.0
Research Services Agreement [Member] | BDI Holdings [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Minimum Obligation For Research and Development | € |  |  |  |  |  |  |  |  |  |  |  |  |  | € 1,000,000
Collaborative Arrangement, Revenue Sharing, Percentage |  | 50.00% | 50.00% |  |  |  |  |  |  |  |  |  |  |
Research Services Agreement [Member] | BDI Holdings [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Revenue Sharing, Percentage |  | 75.00% | 75.00% |  |  |  |  |  |  |  |  |  |  |
Research Services Agreement [Member] | VLPBio Member |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Equity Interest Acquired |  | 3.30% | 3.30% |  |  |  |  |  |  |  |  |  |  |

X
- Definition Represents duration of agreement for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementDurationOfAgreement
Namespace Prefix: | dyai_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents equity interest acquired for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementEquityInterestAcquired
Namespace Prefix: | dyai_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents maximum obligation for research and development for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents minimum obligation for research and development for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents outstanding commitment for collaborative. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementOutstandingCommitment
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents payments for additional development and commercialization for collaborative arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents payment for research and development agreement for collaborate arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents percentage of revenue sharing for collaborate arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementRevenueSharingPercentage
Namespace Prefix: | dyai_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents ownership percentage by noncontrolling owners for noncontrolling interest. + References No definition available. + Details
Name: | dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix: | dyai_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of ownership. + References No definition available. + Details
Name: | dyai_OwnershipPercentage
Namespace Prefix: | dyai_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of investment in equity security without readily determinable fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714 + Details
Name: | us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Balance held at close of period in number of shares. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 50 -Paragraph 6 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -URI http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010 + Details
Name: | us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=dyai_IDBiologicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_NovovetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dyai_BDIHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedContractCostAxis=dyai_ResearchServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedContractCostAxis=dyai_ServiceFrameworkAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_BDIHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_VLPBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_AlphazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_IDBiologicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |